We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Books » Understanding EU Drug Safety Reporting

Other Options

PDF Edition

$397.00

PDF Edition - 3-4 Copies (10% Off)

$357.00

PDF Edition - 5-6 Copies (15% Off)

$337.00

PDF Edition - 7-9 Copies (20% Off)

$317.00

PDF Edition - 10+ Copies (25% Off)

$297.00

Understanding EU Drug Safety Reporting

$397.00
Also Available:
Books

Product Details

Are your pharmaceuticals still safe to sell in Europe?

And how can you tell?

These questions have never been timelier. The new European Pharmacovigilance Risk Assessment Committee (PRAC for short) gets closer to full operation each day. Next year, when it hits full stride, U.S. drug exporters will find themselves playing under all-new rules.

It’s time you got up to speed — and doing so has never been easier.

In an hour or two of study, you’ll gain understanding of new EU pharmacovigilance rules, from preapproval through the life of a drug, plus insight into compliance in a new era. Specifically you’ll discover:

  • How to deal with the PRAC

  • How to tailor a PRAC-ready pharmacovigilance system, including finding and appointing a new “qualified person” (QP) to oversee pharmacovigilance

  • How to adapt to broad new definitions of adverse drug reactions, including monitoring of off-label uses and misuses

  • How to prepare for safety label warning changes to accompany products whenever a regulator requests additional safety monitoring

  • And much more!

The PRAC will be responsible for investigating drug safety, reviewing risk management plans for new drugs, and advising when safety of a drug or class of drugs is in question. Will it be a tiger — or a paper tiger? You need to know — now.

Order Your Copy Today!

PDF Edition

 

Available Format

PDF Edition — $397

Table of Contents

  • Introduction
  • The Creation, Roles and Responsibilities of the PRAC
  • Changes in Marketing Authorization Applications
  • New Postmarket Safety Study Definition and Requirements
  • And More …

View the entire TOC

Multi-user Access

Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Online Library – a personalized collection of FDAnews publications that is fully searchable. Contact Customer Service for a quote or more information.

Our Guarantee

Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing